[CLSTR]
< Back to situations

[ORGANIZATION]

semaglutide

Featured in 33 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [DK]

Novo Nordisk expands GLP-1 pipeline amid patent and M&A head

106 clusters · 512 sources · last updated

Latest: Novo Nordisk shares fall despite ambitious 2030 drug pipeline targets

Novo Nordisk continues to expand its GLP-1 market presence, maintaining approximately a 43% global market share for obesity and diabetes treatments despite competition from Eli Lilly. The oral Wegovy pill remains a prima

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

259 clusters · 928 sources · last updated

Latest: Medical experts warn of weight regain risks for GLP-1 users

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

[ACTIVE] [HEALTH] [US] [GB] [DE]

Expanded therapeutic research and management of GLP-1 drugs

16 clusters · 102 sources · last updated

Latest: Semaglutide may reduce asthma attacks and impact weight maintenance

Medical research continues to expand the known therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. Beyond their primary uses for diabetes and obesity, these medications are being linked to

[QUIET] [HEALTH] [BR]

Semaglutide regulatory approvals and pricing in Brazil

8 clusters · 112 sources · last updated

Latest: Brazil expands access to obesity and diabetes treatments

Brazil’s National Health Surveillance Agency (Anvisa) has expanded the domestic market for semaglutide, a medication used to treat type 2 diabetes and weight loss. Initially, Anvisa registered five new semaglutide inject

[QUIET] [HEALTH] [BR] [MX] [TR]

Body image and GLP-1 medication trends in Brazil

5 clusters · 90 sources · last updated

Latest: GLP-1 weight loss medications spark clinical debate among health professionals

Health experts and regulatory bodies in Brazil are intensifying warnings regarding the use of GLP-1 receptor agonists, such as semaglutide and tirzepatide, for weight loss. While effective for obesity, a systematic revie

[QUIET] [HEALTH] [HR] [US]

GLP-1 drug medical and economic impact

2 clusters · 5 sources · last updated

Latest: Ozempic: mechanism, uses, and weight loss effects

GLP-1 receptor agonist drugs, including semaglutide (the active ingredient in Ozempic), are significantly impacting the treatment of obesity, diabetes, and various cardiovascular and kidney diseases. These medications ha

Also covered in